Impact of the TRPV2 Inhibitor on Advanced Heart Failure in Patients with Muscular Dystrophy: Exploratory Study of Biomarkers Related to the Efficacy of Tranilast

Impact of the TRPV2 Inhibitor on Advanced Heart Failure in Patients with Muscular Dystrophy: Exploratory Study of Biomarkers Related to the Efficacy of Tranilast

Cardiomyopathy is the leading cause of death in patients with muscular dystrophy (MD). Tranilast, a widely used anti-allergic drug, has displayed inhibitory activity against the transient receptor potential cation channel subfamily V member 2 and improved cardiac function in MD patients. To identify...

Full description

Bibliographic Details
Main Authors:	Chisato Takahashi, Mariko Oishi, Yuko Iwata, Keiko Maekawa, Tsuyoshi Matsumura
Format:	Article
Language:	English
Published:	MDPI AG 2023-01-01
Series:	International Journal of Molecular Sciences
Subjects:	muscular dystrophy tranilast transient receptor potential cation channel subfamily V member 2 heart failure brain natriuretic peptide metabolomics
Online Access:	https://www.mdpi.com/1422-0067/24/3/2167

Similar Items

Tranilast for advanced heart failure in patients with muscular dystrophy: a single-arm, open-label, multicenter study
by: Tsuyoshi Matsumura, et al.
Published: (2022-05-01)

Muscular Dystrophy /
by: Naff, Clay Farris, editor 192865, et al.
Published: (2012)

Therapeutic Effects of Long-Term Administration of Tranilast in an Animal Model for the Treatment of Fibroids
by: Tsai-Der Chuang, et al.
Published: (2023-06-01)

A rare case of dystrophinopathy: Duchenne muscular dystrophy–Becker muscular dystrophy intermediate complex
by: Rachna Gulati, et al.
Published: (2022-01-01)

Duchenne muscular dystrophy: an historical treatment review
by: Lineu Cesar Werneck, et al.

Molecular targets to treat muscular dystrophies
by: Jochen Kinter, et al.
Published: (2014-02-01)

Tranilast directly targets NLRP3 to treat inflammasome‐driven diseases
by: Yi Huang, et al.
Published: (2018-04-01)

Development of Sustained-Release Ophthalmic Formulation Based on Tranilast Solid Nanoparticles
by: Misa Minami, et al.
Published: (2020-04-01)

Histone Deacetylases: Molecular Mechanisms and Therapeutic Implications for Muscular Dystrophies
by: Martina Sandonà, et al.
Published: (2023-02-01)

The association of hand grip strength with functional measures in non-ambulatory children with Duchenne muscular dystrophy
by: Numan Bulut, et al.
Published: (2019-12-01)

Eletrophilic Chemistry of Tranilast Is Involved in Its Anti-Colitic Activity via Nrf2-HO-1 Pathway Activation
by: Seongkeun Jeong, et al.
Published: (2021-10-01)

Orofacial Manifestations Associated with Muscular Dystrophies: A Review
by: Petros Papaefthymiou, et al.
Published: (2022-03-01)

Rehabilitation therapy of Duchenne muscular dystrophy
by: Cheng ZHANG, et al.
Published: (2012-06-01)

Novel Cationic Carotenoid Lipids as Delivery Vectors of Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy
by: Vassilia Partali, et al.
Published: (2012-01-01)

Absence of the dystrophin protein in Duchenne muscular dystrophy: effects on transcriptome, proteome and microRNA secretome
by: van Westering, T
Published: (2018)

Validation of Chemokine Biomarkers in Duchenne Muscular Dystrophy
by: Michael Ogundele, et al.
Published: (2021-08-01)

The golden retriever model of Duchenne muscular dystrophy
by: Joe N. Kornegay
Published: (2017-05-01)

The X‐linked Becker muscular dystrophy (bmx) mouse models Becker muscular dystrophy via deletion of murine dystrophin exons 45–47
by: Christopher R. Heier, et al.
Published: (2023-04-01)

Limb-girdle muscular dystrophy type 2B (LGMD2B) caused by pathogenic splice and missense variants of DYSF gene among Iranians with muscular dystrophy
by: Fatemeh Arab, et al.
Published: (2023-01-01)

Dystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies
by: Elisabeth Le Rumeur
Published: (2015-07-01)

Tracking disease progression non‐invasively in Duchenne and Becker muscular dystrophies
by: Pietro Spitali, et al.
Published: (2018-08-01)

An in situ Gelling System Based on Methylcellulose and Tranilast Solid Nanoparticles Enhances Ocular Residence Time and Drug Absorption Into the Cornea and Conjunctiva
by: Noriaki Nagai, et al.
Published: (2020-07-01)

<i>In Silico</i> Fragment-Based Drug Design and Molecular Docking of Tranilast Analogues as Potential Inhibitors of Transforming Growth Factor- β Receptor Type 1
by: Nusaiba A. Babiker, et al.
Published: (2022-11-01)

Health Care Use of Cardiac Specialty Care in Children With Muscular Dystrophy in the United States
by: Erika J. Mejia, et al.
Published: (2022-04-01)

Identification of circulating miRNAs differentially expressed in patients with Limb-girdle, Duchenne or facioscapulohumeral muscular dystrophies
by: José Luis García-Giménez, et al.
Published: (2022-12-01)

Molecular Characterization of Dystrophin Gene in Iraqi Patients with Muscular Dystrophy.
by: Areen T. Ramadhan Al-Hadithi, et al.
Published: (2014-07-01)

Timed immersion expiration measures in patients with muscular dystrophies
by: Mariana Callil Voos, et al.
Published: (2020-02-01)

The evolution of electrocardiographic changes in patients with Duchenne muscular dystrophies
by: Woo Hyun Yoo, et al.
Published: (2017-06-01)

Advances in diagnosis and treatment of limb-girdle muscular dystrophy
by: Meng YU, et al.
Published: (2017-08-01)

P2X7 Receptor Antagonist Reduces Fibrosis and Inflammation in a Mouse Model of Alpha-Sarcoglycan Muscular Dystrophy
by: Lizzia Raffaghello, et al.
Published: (2022-01-01)

The frequency of Duchenne muscular dystrophy/Becker muscular dystrophy and Pompe disease in children with isolated transaminase elevation: results from the observational VICTORIA study
by: Aydan Kansu, et al.
Published: (2023-09-01)

On the Role of Delays to Diagnosis of Facioscapulohumeral Muscular Dystrophy
by: Elan Schonfeld, et al.
Published: (2022-09-01)

Genetic and Clinical Advances of Congenital Muscular Dystrophy
by: Xiao-Na Fu, et al.
Published: (2017-01-01)

Oculopharyngeal muscular dystrophy - an under-diagnosed disorder?
by: M Plasilov, et al.
Published: (2005-10-01)

Mechanisms of Myofibre Death in Muscular Dystrophies: The Emergence of the Regulated Forms of Necrosis in Myology
by: Maximilien Bencze
Published: (2022-12-01)

A comprehensive database of Duchenne and Becker muscular dystrophy patients in Children's Hospital of Fudan University
by: Xi-hua LI, et al.
Published: (2015-05-01)

Analysis of cardiac exams: electrocardiogram and echocardiogram use In Duchenne muscular dystrophies
by: Cynthia Kallás Bachur, et al.

N-terminal domain on dystroglycan enables LARGE1 to extend matriglycan on α-dystroglycan and prevents muscular dystrophy
by: Hidehiko Okuma, et al.
Published: (2023-02-01)

Balance of Drug Residence and Diffusion in Lacrimal Fluid Determine Ocular Bioavailability in In Situ Gels Incorporating Tranilast Nanoparticles
by: Misa Minami, et al.
Published: (2021-09-01)

Laparoscopic suture repair of idiopathic gastric perforation in Duchenne muscular dystrophy
by: Go Miyano, et al.
Published: (2015-01-01)